A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

NCT03633396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Palmoplantar Pustulosis

Interventions

BIOLOGICAL: Imsidolimab
DRUG: Placebo

Sponsor

Vanda Pharmaceuticals